MACROGENICS, INC. (NASDAQ:MGNX) Files An 8-K Other Events
Item 8.01
|
Other Events
|
a press release providing an update on several of the Company’s
product candidates and technology platforms.
and is incorporated herein by reference.
|
Item 9.01
|
Financial Statements and Exhibits
|
|
(d) Exhibits.
|
|
|
99.1
|
Press Release, dated December 13, 2016.
|
About MACROGENICS, INC. (NASDAQ:MGNX)
MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases segment. It develops therapeutic product candidates using its antibody-based technology platforms and in partnership with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily against various cancers. Its product candidates include margetuximab, enoblituzumab, MGD006, MGD007, MGD011, MGD009, MGD013, MGD010, teplizumab and MGD014. Its clinical product candidate, margetuximab, is a monoclonal antibody directed against human epidermal growth factor receptor 2, (HER2), including certain types of breast and gastroesophageal cancers. MACROGENICS, INC. (NASDAQ:MGNX) Recent Trading Information
MACROGENICS, INC. (NASDAQ:MGNX) closed its last trading session down -3.60 at 19.82 with 501,428 shares trading hands.
